Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins... Show more
ENTX is expected to report earnings to fall 257.14% to -10 cents per share on March 27
Q4'25
Est.
$-0.11
Q3'25
Beat
by $0.16
Q2'25
Beat
by $0.05
Q1'25
Beat
by $0.01
Q4'24
Est.
$-0.06
The last earnings report on November 14 showed earnings per share of 7 cents, beating the estimate of -9 cents. With 21.24K shares outstanding, the current market capitalization sits at 122.90M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. ENTX showed earnings on November 14, 2025. You can read more about the earnings report here.